Human leukocyte antigen A2-restricted melanoma-associated peptide (HLA-A2 melanoma peptide)

Human leukocyte antigen A2 (HLA-A2)-restricted melanoma-associated peptides are short protein fragments, typically 8 to 11 amino acids in length, derived from proteins overexpressed in melanoma cells such as gp100, MART-1, and MAGE-A4 [1][3]. These peptides are processed intracellularly and presented on the cell surface by the HLA-A*02:01 molecule, forming a peptide-MHC (pMHC) complex that serves as a specific target for the cellular immune system [3]. CD8+ cytotoxic T lymphocytes recognize these complexes via their T-cell receptors (TCRs), triggering a cascade that results in the destruction of the malignant cell [2]. In modern oncology, these complexes are exploited as therapeutic targets for TCR-engineered T-cell therapies, bispecific T-cell engagers like tebentafusp, and therapeutic cancer vaccines [1][4]. Because HLA-A2 is one of the most prevalent MHC Class I alleles in human populations, these peptides are central to the development of standardized immunotherapies for melanoma [5]. However, clinical challenges include potential off-tumor toxicity against healthy melanocytes in the skin and eyes, as well as the risk of tumor escape through the downregulation of HLA expression [1].

Other names

HLA-A2 melanoma antigensMelanoma-associated antigen (MAA) epitopesHLA-A*02:01-restricted peptidesMelanoma differentiation antigen peptidespMHC complex

Therapeutic agents targeting these complexes function by binding specifically to the unique interface formed by the melanoma peptide and the HLA-A2 molecule, thereby recruiting and activating cytotoxic T-cells to release perforins and granzymes, which leads to the selective lysis of melanoma cells [1][2].